AU583854B2 - Antibody therapeutic agent conjugates - Google Patents

Antibody therapeutic agent conjugates

Info

Publication number
AU583854B2
AU583854B2 AU48071/85A AU4807185A AU583854B2 AU 583854 B2 AU583854 B2 AU 583854B2 AU 48071/85 A AU48071/85 A AU 48071/85A AU 4807185 A AU4807185 A AU 4807185A AU 583854 B2 AU583854 B2 AU 583854B2
Authority
AU
Australia
Prior art keywords
antibody
therapeutic agent
linker
fragment
fab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU48071/85A
Other languages
English (en)
Other versions
AU4807185A (en
Inventor
Vernon Leon Alvarez
Daniel James Coughlan
John Walter Frank Goers
Hurley Dalton King
Chyi Lee
Thomas Joseph Mckearn
John Dennis Rodwell
Richard Charles Siegel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytogen Corp
Original Assignee
Cytogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/650,375 external-priority patent/US4867973A/en
Application filed by Cytogen Corp filed Critical Cytogen Corp
Publication of AU4807185A publication Critical patent/AU4807185A/en
Application granted granted Critical
Publication of AU583854B2 publication Critical patent/AU583854B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0042—Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AU48071/85A 1984-09-13 1985-09-10 Antibody therapeutic agent conjugates Ceased AU583854B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US65075484A 1984-09-13 1984-09-13
US650375 1984-09-13
US06/650,375 US4867973A (en) 1984-08-31 1984-09-13 Antibody-therapeutic agent conjugates
US650754 1984-09-13

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU30161/89A Division AU3016189A (en) 1984-09-13 1989-02-21 Antibody-therapeutic agent conjugate intermediates

Publications (2)

Publication Number Publication Date
AU4807185A AU4807185A (en) 1986-04-08
AU583854B2 true AU583854B2 (en) 1989-05-11

Family

ID=27095841

Family Applications (2)

Application Number Title Priority Date Filing Date
AU48071/85A Ceased AU583854B2 (en) 1984-09-13 1985-09-10 Antibody therapeutic agent conjugates
AU30161/89A Abandoned AU3016189A (en) 1984-09-13 1989-02-21 Antibody-therapeutic agent conjugate intermediates

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU30161/89A Abandoned AU3016189A (en) 1984-09-13 1989-02-21 Antibody-therapeutic agent conjugate intermediates

Country Status (7)

Country Link
EP (1) EP0175617B1 (https=)
AU (2) AU583854B2 (https=)
CA (1) CA1326834C (https=)
DE (1) DE3584559D1 (https=)
DK (1) DK218386A (https=)
GR (1) GR852217B (https=)
WO (1) WO1986001720A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU610104B2 (en) * 1986-11-27 1991-05-16 National Blood Authority Pharmaceutically active conjugates having improved body tissue binding specificity

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5140104A (en) * 1982-03-09 1992-08-18 Cytogen Corporation Amine derivatives of folic acid analogs
US4831122A (en) * 1986-01-09 1989-05-16 Regents Of The University Of Minnesota Radioimmunotoxins
CA1330378C (en) * 1986-05-08 1994-06-21 Daniel J. Coughlin Amine derivatives of folic acid analogs
US4801688A (en) * 1986-05-27 1989-01-31 Eli Lilly And Company Hydrazone immunoglobulin conjugates
US4835258A (en) * 1986-12-24 1989-05-30 Northwestsern University Conjugation of aromatic amines or nitro-containing compounds with proteins or polypeptides by photoirradiation of the azide derivatives with ultraviolet light in order to produce antibodies against the haptens
JPH01502118A (ja) * 1987-01-15 1989-07-27 セルテク・リミテツド チオール反応性架橋剤
US4920143A (en) * 1987-04-23 1990-04-24 University Of British Columbia Hydro-monobenzoporphyrin wavelength-specific cytotoxic agents
US5283255A (en) * 1987-01-20 1994-02-01 The University Of British Columbia Wavelength-specific cytotoxic agents
US5171749A (en) * 1987-01-20 1992-12-15 University Of British Columbia Wavelength-specific cytotoxic agents
US5095030A (en) * 1987-01-20 1992-03-10 University Of British Columbia Wavelength-specific cytotoxic agents
US4883790A (en) * 1987-01-20 1989-11-28 University Of British Columbia Wavelength-specific cytotoxic agents
FR2610198B1 (fr) * 1987-02-03 1990-06-15 Ire Celltarg Sa Conjugues d'hydrazide d'alcaloide de vinca lie a une immunoglobuline, procede de preparation et compositions pharmaceutiques en comprenant
FR2611141B1 (fr) * 1987-02-20 1991-02-01 Int Rech Cancer Centre Ensemble ou kit pour utilisation comme agent pour la destruction selective de cellules transformees ou tumorales
NO881077L (no) * 1987-03-11 1988-09-12 Univ Michigan Kjemo-radio-immuno-konjugater.
US4937183A (en) * 1988-02-03 1990-06-26 Cytogen Corporation Method for the preparation of antibody-fragment conjugates
US5047227A (en) * 1988-02-08 1991-09-10 Cytogen Corporation Novel and improved antibodies for site specific attachment of compounds
EP0336383A3 (en) * 1988-04-07 1990-08-16 Takeda Chemical Industries, Ltd. Novel recombinant human lymphotoxin
USRE39094E1 (en) 1988-07-20 2006-05-09 Health Research, Inc. Pyropheophorbides and their use in photodynamic therapy
USRE38994E1 (en) 1988-07-20 2006-02-28 Health Research, Inc. Pyropheophorbides conjugates and their use in photodynamic therapy
DE3827940A1 (de) * 1988-08-13 1990-03-01 Schering Ag 13,17-propionsaeure- und propionsaeurederivat- substituierte porphyrin-komplexverbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
WO1990003401A1 (en) * 1988-09-30 1990-04-05 Neorx Corporation Targeting substance-diagnostic/therapeutic agent conjugates having schiff base linkages
US5066789A (en) * 1988-09-30 1991-11-19 Neorx Corporation Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages
GR890100827A (el) * 1988-12-21 1991-03-15 Abbott Lab Μέ?οδος παραγωγής παραγώγων τετραπεπτιδίων ως ανταγωνιστών CCK.
US5270302A (en) * 1988-12-21 1993-12-14 Abbott Laboratories Derivatives of tetrapeptides as CCK agonists
US5308608A (en) * 1989-06-07 1994-05-03 University Of British Columbia Photosensitizing Diels-Alder porphyrin derivatives
WO1990015059A1 (en) * 1989-06-07 1990-12-13 The University Of British Columbia Photosensitizing diels-alder porphyrin derivatives
EP0449998A4 (en) * 1989-06-30 1992-01-15 Brunswick Corporation Antibody-oxidase conjugates with non-systemic substrates
WO1991009134A1 (en) * 1989-12-15 1991-06-27 Takeda Chemical Industries, Ltd. Biospecific antibody to cancer cell and enzyme with prodrug-activating characteristics
AU648313B2 (en) * 1990-04-25 1994-04-21 Pharmacia & Upjohn Company Novel CC-1065 analogs
EP0553116A1 (en) * 1990-10-05 1993-08-04 Queen's University At Kingston Porphyrin derivatives
US5272253A (en) * 1991-07-01 1993-12-21 Eli Lilly And Company Cluster conjugates of drugs with antibodies
GR1001459B (el) * 1992-10-08 1993-12-30 Lilly Co Eli Σύμπλεγμα συζυγών φαρμάκων με αντισώματα.
WO1997033620A2 (de) * 1996-03-15 1997-09-18 Pulsion Verw. Gmbh & Co. Medical Systems Kg Verbindungen zur behandlung von tumoren
US7390668B2 (en) 1996-10-30 2008-06-24 Provectus Pharmatech, Inc. Intracorporeal medicaments for photodynamic treatment of disease
US6493570B1 (en) * 1998-11-02 2002-12-10 Photogen, Inc. Method for improved imaging and photodynamic therapy
ITRM960808A1 (it) * 1996-11-26 1998-05-26 Rossolini Gianmaria Immunoconiugati comprendenti anticorpi monoclonali umani o frammenti di essi per diagnosi in vivo e terapia
DE19717904A1 (de) * 1997-04-23 1998-10-29 Diagnostikforschung Inst Säurelabile und enzymatisch spaltbare Farbstoffkonstrukte zur Diagnostik mit Nahinfrarotlicht und zur Therapie
US8557298B2 (en) 1998-08-06 2013-10-15 Provectus Pharmatech, Inc. Medicaments for chemotherapeutic treatment of disease
US7648695B2 (en) * 1998-08-06 2010-01-19 Provectus Pharmatech, Inc. Medicaments for chemotherapeutic treatment of disease
JP2002534218A (ja) 1999-01-15 2002-10-15 ライト サイエンシーズ コーポレイション 非侵襲性の脈管療法
US6454789B1 (en) 1999-01-15 2002-09-24 Light Science Corporation Patient portable device for photodynamic therapy
US6602274B1 (en) 1999-01-15 2003-08-05 Light Sciences Corporation Targeted transcutaneous cancer therapy
KR20020020808A (ko) 1999-08-13 2002-03-15 스무크 존 질병의 광역학적 치료를 위한 국부투여 약물 및 그 방법
EP1267935A2 (en) 2000-01-12 2003-01-02 Light Sciences Corporation Novel treatment for eye disease
EP1654004A2 (en) * 2003-08-08 2006-05-10 Novo Nordisk A/S Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides
EP1697515A4 (en) * 2003-11-12 2008-02-06 Austin Research Inst DNA CARRIER CONJUGATE
US7541330B2 (en) 2004-06-15 2009-06-02 Kosan Biosciences Incorporated Conjugates with reduced adverse systemic effects
EP2380909A1 (en) 2010-04-26 2011-10-26 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. PTK-7 protein involved in breast cancer
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
WO2012021512A2 (en) 2010-08-10 2012-02-16 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
KR102717969B1 (ko) 2014-02-21 2024-10-15 에꼴 뽈리떼끄닉 뻬데랄 드 로잔느 (으뻬에프엘) 글리코타겟팅 치료제
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US11253579B2 (en) 2017-06-16 2022-02-22 The University Of Chicago Compositions and methods for inducing immune tolerance
US20200338128A1 (en) * 2018-01-05 2020-10-29 Gencyte Therapeutics, Inc. Precision molecular adaptor system for car-t immunotherapy
EA202092723A1 (ru) 2018-05-09 2021-04-09 Зе Юниверсити Оф Чикаго Композиции и способы, касающиеся иммунной толерантности

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4419444A (en) * 1975-11-13 1983-12-06 Institut National De La Sante Et De La Recherche Medicale-Inserm Novel supports carrying side chains, processes for obtaining these supports, process for attaching organic compounds having carbohydrate residues one said supports, products and reagents resulting from said chemical fixation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3970521A (en) * 1974-08-07 1976-07-20 Exxon Research And Engineering Company Immobilized glycoenzymes
JPS52141882A (en) * 1976-05-20 1977-11-26 Hidetoshi Tsuchida Highhpolymeric complex of covalent type
CA1203164A (en) * 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4419444A (en) * 1975-11-13 1983-12-06 Institut National De La Sante Et De La Recherche Medicale-Inserm Novel supports carrying side chains, processes for obtaining these supports, process for attaching organic compounds having carbohydrate residues one said supports, products and reagents resulting from said chemical fixation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU610104B2 (en) * 1986-11-27 1991-05-16 National Blood Authority Pharmaceutically active conjugates having improved body tissue binding specificity

Also Published As

Publication number Publication date
AU3016189A (en) 1989-07-13
GR852217B (https=) 1986-01-14
DK218386D0 (da) 1986-05-12
EP0175617A3 (en) 1988-06-15
EP0175617A2 (en) 1986-03-26
EP0175617B1 (en) 1991-10-30
DE3584559D1 (de) 1991-12-05
AU4807185A (en) 1986-04-08
CA1326834C (en) 1994-02-08
DK218386A (da) 1986-07-11
WO1986001720A1 (en) 1986-03-27

Similar Documents

Publication Publication Date Title
AU583854B2 (en) Antibody therapeutic agent conjugates
US5156840A (en) Amine-containing porphyrin derivatives
US4867973A (en) Antibody-therapeutic agent conjugates
EP0088695B1 (en) Antibody conjugates
US4671958A (en) Antibody conjugates for the delivery of compounds to target sites
AU588832B2 (en) Antibody-metal ion complexes
US5112954A (en) Method of enhancing the effect of cytotoxic agents
US4937183A (en) Method for the preparation of antibody-fragment conjugates
US4880935A (en) Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
AU627785B2 (en) Vasopermeability-enhancing conjugates
US4741900A (en) Antibody-metal ion complexes
AU621347B2 (en) Functionally specific antibodies
EP0385601B1 (en) Cross-linked antibodies and processes for their preparation
CA1301066C (en) Anti-tumour substance and process for producing the same
EP0294392A1 (en) DIAGNOSTIC AND THERAPEUTIC CONJUGATES ASSOCIATED WITH ANTIBODY.
US4485093A (en) Immunotoxin conjugate which comprises arsanilic acid, useful for treating malignant tumors, particularly pancreatic cancer
US5354554A (en) Crosslinked antibodies and processes for their preparation
JP3273608B2 (ja) 治療薬の部位特異的インビボ活性化
AU663582B2 (en) In vivo binding pair pretargeting
JP2975676B2 (ja) 架橋抗体とその製法
US6007817A (en) Vasopermeability enhancing immunoconjugates
RU2106147C1 (ru) Конъюгат производного 14-бромдаунорубицина с моноклональным антителом или его фрагментом, обладающий противоопухолевой активностью и имеющий специфичность к данной опухоли, и фармацевтическая композиция, обладающая противоопухолевой активностью
US5714149A (en) Crosslinked antibodies and processes for their preparation
Philpott et al. Selective binding and cytotoxicity of rat basophilic leukemia cells (RBL-1) with immunoglobulin E-biotin and avidin-glucose oxidase conjugates.
EP0485749A2 (en) Chemical modification of antibodies for creating of immunoconjugates